Stangest OncoVet I: Product Profile

Stangest OncoVet I is a named branded product for Dogs and cats as described in the manufacturer oncology materials; manufacturer positioning must be kept separate from independent clinical evidence.

One-gram oral tablets; current manufacturer page lists 60- and 300-tablet presentations. Intended species: Dogs and cats as described in the manufacturer oncology materials.

Per 1 g tablet: L-glutamic acid 150 mg; pomegranate extract 125 mg; milk-thistle extract 100 mg; green-tea extract 100 mg; turmeric extract 50 mg; grape seeds 20 mg; selenium as L-selenomethionine 20 micrograms. The page also lists mineral substances, mono- and diglycerides of behenic acid, magnesium stearate, maltodextrin, and sunflower oil.

Stangest presents OncoVet I as complementary nutritional support for neoplastic disease, including periods with or without chemotherapy or radiotherapy and around surgery. It frames antioxidant and botanical components through cancer-related biological pathways. This is manufacturer positioning, not proof that the product treats a tumor.

May be discussed only as adjunctive/supportive care within a veterinarian-led plan; it must not replace diagnosis, staging, standard treatment, symptom control, or emergency care.

Define a modest supportive goal, objective review date, adverse-effect plan, and stopping rule with the veterinarian.

Bring the current label, lot, complete ingredient panel, seller and country version, and every medicine and supplement to the treating veterinarian.

The current manufacturer page and technical bulletins document composition and ingredient rationale. No randomized controlled canine or feline oncology trial of the complete OncoVet I tablet demonstrating tumor response, reduced recurrence, or survival benefit was identified in the reviewed official sources. Pathway diagrams and ingredient literature do not establish a finished-product clinical outcome.

Green tea, turmeric, pomegranate, grape seed, milk thistle, selenium, and excipients should be reviewed for gastrointestinal tolerance, bleeding, liver metabolism, surgery, chemotherapy, radiotherapy, and duplicate antioxidant exposure. The appropriate relationship between antioxidant supplements and a specific treatment can depend on timing and mechanism; it requires the oncology team, not a universal website rule.

No universal compatibility conclusion is made. Review the complete label and individualized treatment plan with the veterinarian.

The manufacturer identifies OncoVet I as a complementary food/nutritional supplement, not a veterinary medicinal product. No EU veterinary-medicine authorization for cancer treatment was identified. Its legal feed status and packaging may vary by country and should be verified on the local label.

Spain; European Union

Keep the current country-specific package and ingredient panel. Record start date, lot, appetite, vomiting, stool, bruising or bleeding, skin reactions, activity, body weight, and treatment adherence. Laboratory and imaging schedules remain determined by diagnosis and treatment. The team should define a review date and stopping rule for any supportive product.